| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
584.78(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-10-16 |
4 |
AS |
$9.03 |
$22,412 |
D/D |
(2,482) |
334,321 |
|
2% |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-09-14 |
4 |
AS |
$9.89 |
$24,547 |
D/D |
(2,482) |
336,803 |
|
1% |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2023-08-22 |
4 |
AS |
$9.47 |
$17,112 |
D/D |
(1,807) |
340,566 |
|
19% |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-08-20 |
4 |
D |
$9.70 |
$101,472 |
D/D |
(10,461) |
339,285 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2023-08-20 |
4 |
D |
$9.70 |
$101,462 |
D/D |
(10,460) |
342,373 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-08-20 |
4 |
D |
$9.70 |
$153,299 |
D/D |
(15,804) |
1,611,769 |
|
- |
|
| Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
• – – |
2023-08-20 |
4 |
D |
$9.70 |
$69,006 |
D/D |
(7,114) |
261,859 |
|
- |
|
| Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
• – – |
2023-08-20 |
4 |
D |
$9.70 |
$86,446 |
D/D |
(8,912) |
285,297 |
|
- |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-08-11 |
4 |
AS |
$9.99 |
$23,197 |
D/D |
(2,322) |
349,746 |
|
11% |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-07-14 |
4 |
AS |
$9.84 |
$22,848 |
D/D |
(2,322) |
352,068 |
|
6% |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-06-14 |
4 |
AS |
$10.69 |
$24,822 |
D/D |
(2,322) |
354,390 |
|
-13% |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2023-06-08 |
4 |
AS |
$11.13 |
$19,923 |
D/D |
(1,790) |
352,833 |
|
-16% |
|
| Sawaf Aziz |
SVP & CHIEF FINANCIAL OFFICER |
• – – |
2023-05-20 |
4 |
D |
$11.21 |
$98,020 |
D/D |
(8,744) |
268,973 |
|
- |
|
| Grimaud Brett A. |
SVP, GEN COUNSEL AND SECRETARY |
• – – |
2023-05-20 |
4 |
D |
$11.21 |
$128,567 |
D/D |
(11,469) |
294,209 |
|
- |
|
| Winningham Rick E |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-05-20 |
4 |
D |
$11.21 |
$177,163 |
D/D |
(15,804) |
1,627,573 |
|
- |
|
| Farnum Rhonda |
SVP, COMM & MEDICAL AFFAIRS |
• – – |
2023-05-20 |
4 |
D |
$11.21 |
$62,406 |
D/D |
(5,567) |
354,623 |
|
- |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-05-20 |
4 |
D |
$11.21 |
$117,257 |
D/D |
(10,460) |
356,712 |
|
- |
|
| Graham Richard A |
SVP, RESEARCH & DEVELOPMENT |
• – – |
2023-05-15 |
4 |
AS |
$11.26 |
$26,146 |
D/D |
(2,322) |
367,172 |
|
-19% |
|
| Mitchell Dean J |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
70,018 |
|
- |
|
| Smaldone Alsup Laurie |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
53,794 |
|
- |
|
| Oconnor Donal |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
53,018 |
|
- |
|
| Malkiel Burton G |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
100,589 |
|
- |
|
| Pakianathan Deepika |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
36,879 |
|
- |
|
| Gray Susannah |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
20,951 |
|
- |
|
| Broshy Eran |
|
– • – |
2023-05-02 |
4 |
A |
$0.00 |
$0 |
D/D |
9,132 |
70,018 |
|
- |
|
529 Records found
|
|
Page 2 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.03 (0.33%) 
